Child laughing with their mother

NS SUPPORT

Providing personalized access support and customized resources

Our experienced, knowledgeable team at NS Support is dedicated to assisting patients, their caregivers, and healthcare professionals throughout the patient journey to create a smooth path to treatment. We’re committed to being here for you every step of the way.

FOR HEALTHCARE PROFESSIONALS

  • Enroll patients in NS Support using our Patient Start Form
  • Rapid benefits investigation and verification
  • Ongoing, highly responsive reimbursement support and follow-up calls
  • Insights about infusion site options for your patients
  • Streamlined product acquisition options

STARTING YOUR PATIENT ON VILTEPSO?

Here’s what to do:

1.

Download and save the editable Patient Start Form

2.

Submit a completed and signed form to NS Support

  • Via Fax: 888-212-0482
  • Via Mail: NS Support Program, PO Box 29203, Phoenix, AZ 85038-9203

Your completed Patient Start Form with a valid prescriber signature will allow NS Support to start a benefits investigation for your patient. A signed Patient Authorization Form is needed to complete NS Support enrollment, receive program offerings, and enroll in cost support programs if eligible.

More support for physicians and their practices:

FOR PATIENTS AND THEIR CAREGIVERS

  • Individualized, caring support and resources throughout the patient journey
  • Help with understanding insurance coverage for VILTEPSO
  • Co-pay Assistance Program—eligible patients may qualify for savings on their deductible, co-pay, and coinsurance for their medication costs for VILTEPSO*
  • Patient Assistance Program—help for uninsured patients in financial need

PATIENT SUPPORT WITH A PERSONAL TOUCH

Have questions? Call us today. 18336778778 Have questions? Call us today. 18336778778

*

Program covers the cost of the medication only and does not cover the costs to administer the infusion. See full Eligibility Requirements & Terms and Conditions on back of brochure.

RESOURCES

Here are resources that you may find helpful

For Healthcare Providers:

VILTEPSO Overview

Summarizes the clinical evidence of the efficacy and safety of VILTEPSO and other product features

VILTEPSO Dosing and Administration Guide

Provides you with information on how to prescribe, dose, and administer VILTEPSO as infusion therapy

NS Support Resource Guide

Provides information on initiating therapy and helping patients afford their treatment

Infusion Training

A simple step-by-step guide on how to administer an IV infusion for VILTEPSO

Coding & Billing Guide

Provides coding and billing information and sample claim forms for home infusion, physician offices, and hospital outpatient departments (HOPD) to process claims for VILTEPSO


For Patients and Caregivers:

VILTEPSO Overview

Explains the features of VILTEPSO in treating DMD, including efficacy and safety

Getting Started

Answers common questions about what VILTEPSO does, how it works, and other concerns you may have

Patient Support Brochure for VILTEPSO

Introduces patients and caregivers to their NS Pharma and NS Support teams and explains their journey to treatment

Infusion Overview

Helps you better understand the weekly infusion process and address questions with your child in advance of their first session

Affordability Options Brochure

Helps commercially insured patients with their medication costs

Understanding Government-Funded Health Insurance

Provides information about government-funded health insurance and financial assistance

DMD Foundation and Advocacy Groups

Includes a list of foundations and advocacy groups that may be able to provide assistance to patients with DMD

Sign up to receive additional information and updates

Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For more information about VILTEPSO, see full Prescribing Information.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.